<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Int J Fertil Steril</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>International Journal of Fertility &amp; Sterility</journal-title></journal-title-group><issn pub-type="ppub">2008-076X</issn><issn pub-type="epub">2008-0778</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29043702</article-id><article-id pub-id-type="pmc">5641458</article-id><article-id pub-id-type="other">Int-J-Fertil-Steril-11-270</article-id><article-id pub-id-type="doi">10.22074/ijfs.2018.5142</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Pharmacology</subject><subject>Gynecology and Female Infertility</subject></subj-group></subj-group></article-categories><title-group><article-title>N-Acetylcysteine Compared to Metformin, Improves The
Expression Profile of Growth Differentiation Factor-9 and
Receptor Tyrosine Kinase c-Kit in The Oocytes of Patients
with Polycystic Ovarian Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheraghi</surname><given-names>Ebrahim</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Soleimani Mehranjani</surname><given-names>Malek</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Shariatzadeh</surname><given-names>Seyed Mohammad Ali</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nasr Esfahani</surname><given-names>Mohammad Hossein</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Alani</surname><given-names>Behrang</given-names></name><degrees>Ph.D</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><aff id="A1"><label>1</label>Department of Biology, Faculty of Sciences, University of Qom, Qom, Iran</aff><aff id="A2"><label>2</label>Department of Biology, Faculty of Science, Arak University, Arak, Iran</aff><aff id="A3"><label>3</label>Department of Reproductive Biotechnology, Reproductive Biomedicine Research Center, Royan Institute, ACECR,
Isfahan, Iran</aff><aff id="A4"><label>4</label>Department of Applied Cell Science, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran</aff></contrib-group><author-notes><corresp id="cor1"><label>*Corresponding Address:</label><addr-line>P.O.Box: 381-5688138</addr-line><addr-line>Department of Biology</addr-line><addr-line>Faculty of Science</addr-line><institution>Arak University</institution><addr-line>Sardasht</addr-line><addr-line>Arak</addr-line><country>Iran</country>
Email: <email>M-soleimani@araku.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2018</year></pub-date><pub-date pub-type="epub"><day>14</day><month>10</month><year>2017</year></pub-date><volume>11</volume><issue>4</issue><fpage>270</fpage><lpage>278</lpage><history><date date-type="received"><day>11</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium, with the exception of commercial purposes, is permitted provided the original work is properly cited</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
</license-p></license></permissions><abstract><sec><title><offsets xml_i="4335" xml_f="4345" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4356" xml_f="4774" txt_i="22" txt_f="440">Paracrine disruption of growth factors in women with polycystic ovarian syndrome (PCOS) results in
production of low quality oocyte, especially following ovulation induction. The aim of this study was to investigate
the effects of metformin (MET), N-acetylcysteine (NAC) and their combination on the hormonal levels and expres-
sion profile of GDF-9, BMP-15 and c-kit, as hallmarks of oocyte quality, in PCOS patients.</offsets></p></sec><sec><title><offsets xml_i="4796" xml_f="4817" txt_i="442" txt_f="463">Materials and Methods</offsets></title><p><offsets xml_i="4828" xml_f="5463" txt_i="464" txt_f="1099">This prospective randomized, double-blind, placebo controlled trial aims to study the effects
of MET, NAC and their combination (MET+NAC) on expression of GDF-9, BMP-15 and c-kit mRNA in oocytes
[10 at the germinal vesicle (GV) stage, 10 at the MI stage, and 10 at the MII stage from per group] derived following
ovulation induction in PCOS. Treatment was carried out for six weeks, starting on the third day of previous cycle until
oocyte aspiration. The expression of GDF9, BMP15 and c-kit were determined by quantitative real time polymerase
chain reaction (RT-qPCR) and western blot analysis. Data were analyzed with one-way ANOVA.</offsets></p></sec><sec><title><offsets xml_i="5485" xml_f="5492" txt_i="1101" txt_f="1108">Results</offsets></title><p><offsets xml_i="5503" xml_f="6226" txt_i="1109" txt_f="1826">The follicular fluid (FF) level of c-kit protein significantly decreased in the NAC group compared to the other
groups. Significant correlations were observed between the FF soluble c-kit protein with FF volume, androstenedione
and estradiol. The GDF-9 expression in unfertilized mature oocytes were significantly higher in the NAC group com-
pared to the other groups (P&lt;0.001). Similar difference was not observed between the MET, NAC+MET and control
groups. The c-kit expression in unfertilized mature oocytes were significantly lower in the NAC group compared to
the other groups (P&lt;0.001). Similar difference was not observed between the MET, NAC+MET and control groups
(Registration number: IRCT201204159476N1).</offsets></p></sec><sec><title><offsets xml_i="6248" xml_f="6258" txt_i="1828" txt_f="1838">Conclusion</offsets></title><p><offsets xml_i="6269" xml_f="6334" txt_i="1839" txt_f="1904">We concluded that NAC can improve the quality of oocytes in PCOS.</offsets></p></sec></abstract><kwd-group><kwd>Gene Expression</kwd><kwd>Metformin</kwd><kwd>N-acetylcysteine</kwd><kwd>Oocyte</kwd><kwd>Polycystic Ovarian Syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Cheraghi E, Soleimani Mehranjani M, Shariatzadeh SMA, Nasr Esfahani MH, Alani B. N-acetylcysteine compared to metformin, improves the expression
profile of growth differentiation factor-9 and receptor tyrosine kinase c-kit in the oocytes of patients with polycystic ovarian syndrome. Int J Fertil Steril. 2018; 11(4):
270-278 . 10.22074/ijfs.2018.5142.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="7038" xml_f="7050" txt_i="1913" txt_f="1925">Introduction</offsets></title><p><offsets xml_i="7061" xml_f="7197" txt_i="1926" txt_f="2062">Anovulation associated with polycystic ovary syndrome (PCOS), as a common metabolic disorder, is the major cause of female infertility (</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="7228" xml_f="7229" txt_i="2062" txt_f="2063">1</offsets></xref><offsets xml_i="7236" xml_f="7237" txt_i="2063" txt_f="2064">,</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="7268" xml_f="7269" txt_i="2064" txt_f="2065">2</offsets></xref><offsets xml_i="7276" xml_f="7517" txt_i="2065" txt_f="2306">). The principal feature of PCOS is the large number of follicles arresting at early growth stage. The cytoplasmic and nuclear maturity of oocytes is reduced following ovarian stimulation and may account for embryo quality in these couples (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="7548" xml_f="7549" txt_i="2306" txt_f="2307">3</offsets></xref><offsets xml_i="7556" xml_f="7728" txt_i="2307" txt_f="2479">). Exclusive oocyte secreted factors (OSFs), such as growth differentiation factor-9 (GDF-9) and bone morphogenetic factor-15 (BMP-15), belonging to for oocyte competence (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="7759" xml_f="7760" txt_i="2479" txt_f="2480">3</offsets></xref><offsets xml_i="7767" xml_f="7768" txt_i="2480" txt_f="2481">,</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="7799" xml_f="7800" txt_i="2481" txt_f="2482">5</offsets></xref><offsets xml_i="7807" xml_f="7923" txt_i="2482" txt_f="2598">). The receptor tyrosine kinase c-kit is another OSFs which plays important role in oogenesis and folliculogenesis (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="7954" xml_f="7955" txt_i="2598" txt_f="2599">6</offsets></xref><offsets xml_i="7962" xml_f="8072" txt_i="2599" txt_f="2709">). Recent evidence suggest possible involvement of c-kit and its receptor, kit ligand (KL) in PCOS pathology (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="8103" xml_f="8104" txt_i="2709" txt_f="2710">7</offsets></xref><offsets xml_i="8111" xml_f="8291" txt_i="2710" txt_f="2890">). Indeed, it has been shown that the aberrant or low expression of these exclusive oocyte secreting factors (BMP-15 and GDF-9), lead to over expression of c-kit and its receptor (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="8322" xml_f="8323" txt_i="2890" txt_f="2891">8</offsets></xref><offsets xml_i="8330" xml_f="8331" txt_i="2891" txt_f="2892">-</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="8363" xml_f="8365" txt_i="2892" txt_f="2894">10</offsets></xref><offsets xml_i="8372" xml_f="8509" txt_i="2894" txt_f="3031">). Therefore, drugs which can modulate the regulation of these intra-ovarian factors may play a role in the clinical management of PCOS. </offsets></p><p><offsets xml_i="8516" xml_f="8846" txt_i="3032" txt_f="3362">To improve the quality of oocyte, various protocol tion induction along with insulin-sensitizing drugs in PCOS patients. But, the risks of poor response, ovarian hyperstimulation, production of low quality oocytes, reduced fertilization rates and poor embryo quality remains among concern to be dealt within PCOS women undergoing </offsets><italic><offsets xml_i="8854" xml_f="8862" txt_i="3362" txt_f="3370">in vitro</offsets></italic><offsets xml_i="8871" xml_f="8936" txt_i="3370" txt_f="3435"> fertilization (IVF) or intracytoplasmic sperm injection (ICSI) (</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="8968" xml_f="8970" txt_i="3435" txt_f="3437">11</offsets></xref><offsets xml_i="8977" xml_f="9111" txt_i="3437" txt_f="3571">). Metformin, an insulin-lowering agent, has been extensively used for treatment of anovulation and infertility in PCOS patients. ed (</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="9143" xml_f="9145" txt_i="3571" txt_f="3573">12</offsets></xref><offsets xml_i="9152" xml_f="9323" txt_i="3573" txt_f="3744">). In this regard, background studies indicate that MET does not improve the overall outcomes of assisted reproductive procedure in term of the aforementioned parameters (</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="9355" xml_f="9357" txt_i="3744" txt_f="3746">13</offsets></xref><offsets xml_i="9364" xml_f="9365" txt_i="3746" txt_f="3747">,</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="9397" xml_f="9399" txt_i="3747" txt_f="3749">14</offsets></xref><offsets xml_i="9406" xml_f="9409" txt_i="3749" txt_f="3752">). </offsets></p><p><offsets xml_i="9416" xml_f="9735" txt_i="3753" txt_f="4072">On the contrary, administration of N-acetylcysteine (NAC) has been shown to improve not only the number and also the quality of oocytes in these patients. This phenomenon has been mainly related to the strong antioxidant effect of NAC, which has been shown to reduce follicle atresia and improve the quality of oocyte (</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="9767" xml_f="9769" txt_i="4072" txt_f="4074">15</offsets></xref><offsets xml_i="9776" xml_f="9779" txt_i="4074" txt_f="4077">). </offsets><italic><offsets xml_i="9787" xml_f="9795" txt_i="4077" txt_f="4085">In vitro</offsets></italic><offsets xml_i="9804" xml_f="9914" txt_i="4085" txt_f="4195">, NAC plays a key role in cell survival through the production of trophic factor and follicular preservation (</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="9946" xml_f="9948" txt_i="4195" txt_f="4197">16</offsets></xref><offsets xml_i="9955" xml_f="9956" txt_i="4197" txt_f="4198">,</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="9988" xml_f="9990" txt_i="4198" txt_f="4200">17</offsets></xref><offsets xml_i="9997" xml_f="10377" txt_i="4200" txt_f="4580">). In line with these reports, Sacinositol and NAC improve ovarian function of PCOS patients. Therefore, considering the fact that oocyte secretory factors are hallmarks of oocyte quality, this study aims to evaluate the effects of NAC, MET and their co-administration on the expression of GDF-9, BMP-15 and c-kit in PCOS individuals undergoing ovarian stimulation in ICSI cycle. </offsets></p></sec><sec sec-type="materials-methods"><title><offsets xml_i="10428" xml_f="10449" txt_i="4582" txt_f="4603">Materials and Methods</offsets></title><p><offsets xml_i="10460" xml_f="10868" txt_i="4604" txt_f="5012">Antibodies directed against c-kit and β-actin was
obtained from Cell Signaling Technology (Beverly,
MA, USA). BMP-15 antibody was obtained from Abcam
Technology (Cambridge, MA, USA) and GDF-9
antibody from Santa Cruz Biotechnology (CA, USA).
Other reagents used in this study were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Cell culture media
and sera were obtained from Gibco BRL (Carlsbad,
CA, USA).</offsets></p><sec><title><offsets xml_i="10884" xml_f="10896" txt_i="5013" txt_f="5025">Study design</offsets></title><p><offsets xml_i="10907" xml_f="11305" txt_i="5026" txt_f="5424">This study was performed in continuation of our prospective
randomized, double-blind, placebo controlled
trial, in the IVF Unit of Infertility Research Center of
the Academic Center for Education, Culture and Research
(ACECR), Qom/Iran. 80 infertile PCOS women
at the age of 25-35 years, in the interval between
July 2012 and February 2013, who planned to undergo
ICSI were included in this study (</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="11337" xml_f="11339" txt_i="5424" txt_f="5426">19</offsets></xref><offsets xml_i="11346" xml_f="11431" txt_i="5426" txt_f="5511">). Individuals were
diagnosed as PCOS according to the Rotterdam consensus
workshop (</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="11463" xml_f="11465" txt_i="5511" txt_f="5513">20</offsets></xref><offsets xml_i="11472" xml_f="11794" txt_i="5513" txt_f="5835">). Based on this consensus, each
individual needed to have two out of three criteria: i.
Biochemical or clinical hyperandrogenism, ii. Chronic
oligo or anovulation and iii. Polycystic ovaries at ultrasound
examination. Ethical consideration and further
information on this clinical trial are provided in previous
studies (</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="11826" xml_f="11828" txt_i="5835" txt_f="5837">19</offsets></xref><offsets xml_i="11835" xml_f="12105" txt_i="5837" txt_f="6107">). This study was approved by the Ethics
Committee (EC/91/1041) of Royan Institute, Tehran,
Iran. The patients provided an informed consent and
committed to avoid any changes in their normal physical
activity, diet or starting a new medical regimen
throughout the study.</offsets></p></sec><sec><title><offsets xml_i="12127" xml_f="12167" txt_i="6109" txt_f="6149">Treatment design and ovulation induction</offsets></title><p><offsets xml_i="12178" xml_f="12732" txt_i="6150" txt_f="6704">The female partner of ICSI candidates were examined
and randomly divided into 4 groups (n=20): i.
Placebo (PLA) receiving oral rehydration solution
(ORS, Poursina, Iran), ii. MET receiving MET (Glucophage,
Merck, West Drayton, UK, 500 mg), iii.
NAC receiving NAC (Holzkrichen, Germany, batch
no. 6N5483, 600 mg) and iv. MET+NAC group receiving
the combination of MET and NAC at the
aforementioned doses. Treatment was carried out
three times daily for a period of six weeks. The dose
and duration of NAC treatment was chosen according
to recent studies (</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="12764" xml_f="12766" txt_i="6704" txt_f="6706">21</offsets></xref><offsets xml_i="12773" xml_f="12774" txt_i="6706" txt_f="6707">-</offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="12806" xml_f="12808" txt_i="6707" txt_f="6709">23</offsets></xref><offsets xml_i="12815" xml_f="12817" txt_i="6709" txt_f="6711">).</offsets></p><p><offsets xml_i="12824" xml_f="12880" txt_i="6712" txt_f="6768">Gonadotropin-releasing hormone (GnRH) agonist
protocol (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="12912" xml_f="12914" txt_i="6768" txt_f="6770">18</offsets></xref><offsets xml_i="12921" xml_f="13693" txt_i="6770" txt_f="7542">) was used to induce ovulation. The female
partner of ICSI candidates randomized to four groups
received PLA, MET, NAC or MET+NAC from the third
day of last menstrual period (LMP) of previous cycle
until the day of oocyte aspiration. Oral contraceptive
pills (OCPs) were also included in the regimen for 21
days starting simultaneously with placebo, MET, NAC
or MET+NAC on the day 3 of menstrual cycle prior
to the treatment cycle. For ovarian down-regulation,
daily injections of Bucerelin acetate (1 mg, Suprefact,
Aventis, Germany) were administered from the day 19
of the preceding, menstrual cycle until day 2 of the next
cycle. On the second day on the next cycle if the endometrial
thickness was less than 4 mm, the dose of
Burcerelin acetate was reduced to 0.5 mg.</offsets></p><p><offsets xml_i="13700" xml_f="14621" txt_i="7543" txt_f="8464">Ovulation induction was induced from the day two of
the cycle with average daily injections of 2 ampoules
of recombinant follicle stimulating hormone (rFSH,
Gonal-f, Merck Serono S.A., Geneva, Switzerland).
Vaginal ultrasound (Honda Electronics HS 4000-Japan)
was also used to monitor the cycles. 10,000 IU
human chorionic gonadotropin (hCG, Pregnyl, Organon,
Netherlands) was administered to induce ovulation.
36 hours after the administration of hCG, when at
least three follicles had reached the diameters of 16-18
mm, transvaginal oocyte aspiration was performed under
ultrasound guidance and general anesthesia. This
protocol of induction ovulation was used for all the individuals
in the 4 group. During the treatment the participants were asked to report any probable side effects
such as abdominal discomfort, diarrhea and nausea.
Due to these side effects, 20 couples (5 per group) were
excluded from the study (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14651" xml_f="14657" txt_i="8464" txt_f="8470">Fig .1</offsets></xref><offsets xml_i="14664" xml_f="14666" txt_i="8470" txt_f="8472">).</offsets></p></sec><sec><title><offsets xml_i="14688" xml_f="14746" txt_i="8474" txt_f="8532">Preparation of oocytes, follicular fluid and blood samples</offsets></title><p><offsets xml_i="14757" xml_f="14889" txt_i="8533" txt_f="8665">Based on our pervious study, oocytes and follicular
fluid (FF) from multiple follicles, from each subject
were pooled as explained (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="14921" xml_f="14923" txt_i="8665" txt_f="8667">18</offsets></xref><offsets xml_i="14930" xml_f="15229" txt_i="8667" txt_f="8966">). Following oocyte retrieval,
their cumulus cells were removed by exposure
to 20 IU/ml hyaluronidase (ART-4007A, SAGE BioPharma,
USA) in HEPES-based medium for 30 seconds
followed by mechanical pipetting in HEPES-buffered
HTF containing 5 mg/ml human serum albumin (ART-
3001, SAGE BioPharma, USA).</offsets></p><p><offsets xml_i="15236" xml_f="15924" txt_i="8967" txt_f="9655">The nuclear status of each oocyte was determined
under the stereo microscope (Olympus Co., Japan) and
classified into three categories: i. Unfertilized mature
oocyte [metaphase II (MII)] following ICSI, ii. Germinal
vesicle (GV) stage, iii. Without first polar body
called metaphase I (MI). For gene expression analysis,
in each experimental group, 10 GV, 10 MI, and 10 MII
oocytes were separately pooled and washed in phosphate-
buffered saline (PBS) and transferred into RNasefree
microcentrifuge tubes. 50 μl of RNAlater, RNA Stabilization
Reagent (Qiagen, USA) were added to each
tube and all samples were stored in a -80°C freezer until
analysis. Only MII oocytes were used for ICSI.</offsets></p><p><offsets xml_i="15931" xml_f="16458" txt_i="9656" txt_f="10183">The FF, from the first aspirated with no visible blood
contamination was collect and immediately centrifuged
at 3000 rpm for 10 minutes, and the supernatants
were stored at -70°C for further analysis. Fasting
blood sample were also collected from each participant
once prior to the start of treatment (day 2 of pervious
cycle) and once on the day of ovum pick up of ICSI
cycle. The samples were immediately centrifuged for
10 minutes at 3000 rpm (Hettich, EBA20, UK) and the
resulting serum were stored at -70°C for evaluation.</offsets></p><p><offsets xml_i="16465" xml_f="16986" txt_i="10184" txt_f="10705">The levels of luteinizing hormone (LH, mIU/ml), FSH
(mIU/ml), total testosterone (TT, ng/ml), Progesterone
(ng/ml), estradiol (E2, pg/ml) and androstenedione (ng/
ml) in the FF and serum were measured in all samples
using the ELISA enzyme immunoassay (Demeditec Diagnostics
GmbH, Germany) according to the manufacturer’s
protocol. The FF soluble protein level of c-Kit (pg/ml)
was measured with the ELISA Kit (Abnova Corporation,
Taiwan) by sandwich enzyme immunoassay technique,
according to the manufacturer’s protocol.</offsets></p><fig id="F1" orientation="portrait" position="float"><label><offsets xml_i="17050" xml_f="17055" txt_i="10706" txt_f="10711">Fig.1</offsets></label><caption><p><offsets xml_i="17075" xml_f="17115" txt_i="10711" txt_f="10751">Flowchart of participants in this study.</offsets></p><p><offsets xml_i="17122" xml_f="17178" txt_i="10752" txt_f="10808">MET; Metformin, NAC; N-acetylcysteine, and PLA; Placebo.</offsets></p></caption><graphic xlink:href="Int-J-Fertil-Steril-11-270-g01"></graphic></fig></sec><sec><title><offsets xml_i="17279" xml_f="17303" txt_i="10810" txt_f="10834">Gene expression analysis</offsets></title><p><offsets xml_i="17314" xml_f="17893" txt_i="10835" txt_f="11414">Total RNA from the oocytes of each group were isolated
using the EZ-10 total RNA mini-prep Kit (Bio
Basic Inc., Canada), according to the manufacturer's
protocol. All samples were stored at -80ºC till
analysis. Complementary DNA (cDNA) was synthesized,
using random hexamers [using the RevertAid
First Strand cDNA synthesis Kit (Thermo scientific,
USA)]. To determine the relative expression of target
genes, quantitative real time polymerase chain reaction
(RT-qPCR) was carried out using SYBR-Green/
ROX qPCR master mix assay (Thermo scientific,
USA) by gene-specific primers (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="17925" xml_f="17932" txt_i="11414" txt_f="11421">Table 1</offsets></xref><offsets xml_i="17939" xml_f="18037" txt_i="11421" txt_f="11519">). Relative
gene expression was calculated as the abundance ratio
of each target gene relative to </offsets><italic><offsets xml_i="18045" xml_f="18052" txt_i="11519" txt_f="11526">β-actin</offsets></italic><offsets xml_i="18061" xml_f="18187" txt_i="11526" txt_f="11652">. The ABI
step one plus (ABI, USA) instrument was used for
real time PCR experiments and the ΔΔCt method for
data calculation.</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="18258" xml_f="18265" txt_i="11653" txt_f="11660">Table 1</offsets></label><caption><p><offsets xml_i="18285" xml_f="18402" txt_i="11660" txt_f="11777"> Identity and sequence details of polymerase chain reaction (PCR) primers used to analyses mRNA expression in oocytes</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="2" rowspan="1"><hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="18556" xml_f="18579" txt_i="11778" txt_f="11801">Sequence primer (5´-3´)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="18625" xml_f="18629" txt_i="11801" txt_f="11805">Gene</offsets></th></tr><tr><th colspan="2" rowspan="1"><hr></hr></th></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18735" xml_f="18778" txt_i="11805" txt_f="11848">F: CCAATAGAAGTCACCTCR: GCGATCCAGGTTAAATAGCA</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="18811" xml_f="18816" txt_i="11849" txt_f="11854">GDF-9</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18871" xml_f="18917" txt_i="11855" txt_f="11901">F: CAGTCCTCTATTGCCCTTCTR: AATGGTGCGGTTCTCTCTA </offsets></td><td rowspan="1" colspan="1"><offsets xml_i="18950" xml_f="18956" txt_i="11902" txt_f="11908">BMP-15</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19011" xml_f="19060" txt_i="11909" txt_f="11958">F: ACGAATGAGAATAAGCAGAATGAAR: GAGAGGACAGCGGACCAG </offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19093" xml_f="19098" txt_i="11959" txt_f="11964">c-Kit</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19153" xml_f="19199" txt_i="11965" txt_f="12011">F: GGACTTCGAGCAAGAGATGGR: AGCACTGTGTTGGCGTACAG</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="19232" xml_f="19239" txt_i="12012" txt_f="12019">β-actin</offsets></td></tr><tr><th colspan="2" rowspan="1"><hr></hr></th></tr></tbody></table></table-wrap><p><offsets xml_i="19332" xml_f="20271" txt_i="12020" txt_f="12959">Total proteins from each pool of oocytes were extracted
using RIPA lysis and extraction buffer Kit (Cat No:
89900, Thermo Scientific, USA), according to the manufacturer’s
instruction. Concentration of proteins was determined
according to Bradford’s method using bovine
serum albumin (BSA) as a reference standard (Bradford,
1976). Total proteins were electrophoresed in 12.5% sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gel, transferred to polyvinylidene fluoride
membranes, and probed with specific antibodies. Membranes
were developed using enhanced chemiluminescence
reagents (Amersham Bioscience, USA) and the
intensity of immunoreactive polypeptides was analyzed
subsequent to visualization of the bands developed on a
photographic film. Protein bands on photographic film
were quantified by densitometry scanning after background
subtraction. Integrated densities of bands were
measured by Image J software.</offsets></p></sec><sec><title><offsets xml_i="20293" xml_f="20303" txt_i="12961" txt_f="12971">Statistics</offsets></title><p><offsets xml_i="20314" xml_f="20747" txt_i="12972" txt_f="13402">The normality of continuous variables was confirmed
using the Kolmogrov-Smirnov test and data were reported
as means ± SEM. Data analysis were performed using
one-way ANOVA and Tukey’s test for post-hoc. Means
were considered significantly different at P&lt;0.05. Pearson’s
correlation test defined the relation between variables.
All data were analyzed with the statistical software
SPSS (version16.0 for windows, Chicago, IL, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="20794" xml_f="20801" txt_i="13405" txt_f="13412">Results</offsets></title><p><offsets xml_i="20812" xml_f="20981" txt_i="13413" txt_f="13582">Patients characteristics including age, body mass index
(BMI), the level of LH, FSH, E2 and TT were not significantly
different among the groups PCOS prior to treatment.</offsets></p><sec><title><offsets xml_i="20997" xml_f="21022" txt_i="13583" txt_f="13608">Follicular fluid analysis</offsets></title><p><offsets xml_i="21033" xml_f="21136" txt_i="13609" txt_f="13709">
FF volume and FF level of androstenedione, E2 and
progesterone were similar in all groups (P&gt;0.05, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="21168" xml_f="21175" txt_i="13709" txt_f="13716">Table 2</offsets></xref><offsets xml_i="21182" xml_f="21528" txt_i="13716" txt_f="14059">),
but the level of soluble c-kit protein in the FF significantly
decreased in the NAC group compared to other groups
(P&lt;0.01). Our results also showed a significant correlation
between the soluble c-kit protein in the FF of all the
population with the FF volume (r=0.508, P=0.02), androstenedione
(r=0.682, P=0.01), and E2 (r=0.638, P=0.01)
(</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="21558" xml_f="21564" txt_i="14059" txt_f="14065">Fig .2</offsets></xref><offsets xml_i="21571" xml_f="21573" txt_i="14065" txt_f="14067">).</offsets></p></sec><sec><title><offsets xml_i="21595" xml_f="21634" txt_i="14069" txt_f="14108">Evaluation of oocyte and embryo quality</offsets></title><p><offsets xml_i="21645" xml_f="22291" txt_i="14109" txt_f="14740">The number of immature oocytes (MI+GV) and abnormal
mature oocytes significantly decreased in the NAC
group (P&lt;0.01) compared to the other groups. Similar
reduction was also observed in MET and MET+NAC
groups but the reduction was not significant compared
to the placebo group (P&gt;0.05). The fertilization rate of
metaphase II oocytes were similar in all groups (P&gt;0.05).
The number of good embryo (grade I) on day 3 showed a
significant increase in the NAC group (P&lt;0.02) compared
to placebo group. This improvement was also observed in
the MET and MET+NAC groups when compared to the
placebo (P&gt;0.05), but remained insignificant (</offsets><xref ref-type="fig" rid="F3"><offsets xml_i="22321" xml_f="22327" txt_i="14740" txt_f="14746">Fig .3</offsets></xref><offsets xml_i="22334" xml_f="22440" txt_i="14746" txt_f="14852">). The
percentage of top grad embryos was not different between
the three NAC with MET and MET+NAC groups.</offsets></p><table-wrap id="T2" orientation="portrait" position="float"><label><offsets xml_i="22511" xml_f="22518" txt_i="14853" txt_f="14860">Table 2</offsets></label><caption><p><offsets xml_i="22538" xml_f="22616" txt_i="14860" txt_f="14938"> Comparison of the biochemical parameters of follicular fluid in PCOS patients</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1"><hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="22770" xml_f="22773" txt_i="14939" txt_f="14942">PlA</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22819" xml_f="22826" txt_i="14942" txt_f="14949">NAC+MET</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22872" xml_f="22875" txt_i="14949" txt_f="14952">MET</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22921" xml_f="22924" txt_i="14952" txt_f="14955">NAC</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22970" xml_f="22979" txt_i="14955" txt_f="14964">Parameter</offsets></th></tr><tr><th colspan="5" rowspan="1"><hr></hr></th></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23085" xml_f="23113" txt_i="14964" txt_f="14992">Follicular fluid Volume (ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23146" xml_f="23156" txt_i="14993" txt_f="15003">5.4 ± 1.13</offsets><sup><offsets xml_i="23161" xml_f="23162" txt_i="15003" txt_f="15004">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23201" xml_f="23210" txt_i="15005" txt_f="15014">5.7 ± 1.1</offsets><sup><offsets xml_i="23215" xml_f="23216" txt_i="15014" txt_f="15015">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23255" xml_f="23265" txt_i="15016" txt_f="15026">4.96 ± 1.1</offsets><sup><offsets xml_i="23270" xml_f="23271" txt_i="15026" txt_f="15027">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23310" xml_f="23319" txt_i="15028" txt_f="15037">4.9 ± 1.1</offsets><sup><offsets xml_i="23324" xml_f="23325" txt_i="15037" txt_f="15038">a</offsets></sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23386" xml_f="23403" txt_i="15039" txt_f="15056">Estradiol (pg/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23436" xml_f="23448" txt_i="15057" txt_f="15069">466.6 ± 34.8</offsets><sup><offsets xml_i="23453" xml_f="23454" txt_i="15069" txt_f="15070">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23493" xml_f="23505" txt_i="15071" txt_f="15083">496.6 ± 44.8</offsets><sup><offsets xml_i="23510" xml_f="23511" txt_i="15083" txt_f="15084">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23550" xml_f="23562" txt_i="15085" txt_f="15097">470.2 ± 48.4</offsets><sup><offsets xml_i="23567" xml_f="23568" txt_i="15097" txt_f="15098">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23607" xml_f="23618" txt_i="15099" txt_f="15110">436 ± 40.16</offsets><sup><offsets xml_i="23623" xml_f="23624" txt_i="15110" txt_f="15111">a</offsets></sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23685" xml_f="23705" txt_i="15112" txt_f="15132">Progesterone (ng/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23738" xml_f="23752" txt_i="15133" txt_f="15147">3983.7 ± 353.9</offsets><sup><offsets xml_i="23757" xml_f="23758" txt_i="15147" txt_f="15148">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23797" xml_f="23811" txt_i="15149" txt_f="15163">3916.9 ± 359.5</offsets><sup><offsets xml_i="23816" xml_f="23817" txt_i="15163" txt_f="15164">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23856" xml_f="23870" txt_i="15165" txt_f="15179">3501.2 ± 326.9</offsets><sup><offsets xml_i="23875" xml_f="23876" txt_i="15179" txt_f="15180">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="23915" xml_f="23929" txt_i="15181" txt_f="15195">3255.3 ± 414.8</offsets><sup><offsets xml_i="23934" xml_f="23935" txt_i="15195" txt_f="15196">a</offsets></sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23996" xml_f="24019" txt_i="15197" txt_f="15220">Androstenedione (ng/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24052" xml_f="24064" txt_i="15221" txt_f="15233">426.2 ± 30.3</offsets><sup><offsets xml_i="24069" xml_f="24070" txt_i="15233" txt_f="15234">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24109" xml_f="24121" txt_i="15235" txt_f="15247">435.2 ± 46.7</offsets><sup><offsets xml_i="24126" xml_f="24127" txt_i="15247" txt_f="15248">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24166" xml_f="24178" txt_i="15249" txt_f="15261">487.6 ± 42.9</offsets><sup><offsets xml_i="24183" xml_f="24184" txt_i="15261" txt_f="15262">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24223" xml_f="24236" txt_i="15263" txt_f="15276">548.3 ± 42.36</offsets><sup><offsets xml_i="24241" xml_f="24242" txt_i="15276" txt_f="15277">a</offsets></sup></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="24303" xml_f="24324" txt_i="15278" txt_f="15299">Soluble c-Kit (pg/ml)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24357" xml_f="24369" txt_i="15300" txt_f="15312">317.8 ± 27.5</offsets><sup><offsets xml_i="24374" xml_f="24375" txt_i="15312" txt_f="15313">b</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24414" xml_f="24426" txt_i="15314" txt_f="15326">380.8 ± 30.3</offsets><sup><offsets xml_i="24431" xml_f="24432" txt_i="15326" txt_f="15327">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24471" xml_f="24483" txt_i="15328" txt_f="15340">429.8 ± 28.7</offsets><sup><offsets xml_i="24488" xml_f="24489" txt_i="15340" txt_f="15341">a</offsets></sup></td><td rowspan="1" colspan="1"><offsets xml_i="24528" xml_f="24541" txt_i="15342" txt_f="15355">455.2 ± 28.75</offsets><sup><offsets xml_i="24546" xml_f="24547" txt_i="15355" txt_f="15356">a</offsets></sup></td></tr><tr><th colspan="5" rowspan="1"><hr></hr></th></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="24654" xml_f="24758" txt_i="15357" txt_f="15461">Data are shown as mean ± SEM. Analysis was performed by ANOVA and Tukey’s test for multiple comparisons.</offsets></p><p><offsets xml_i="24765" xml_f="24931" txt_i="15462" txt_f="15625">Means without a common letter are significantly different (P&lt;0.05). PCOS; Polycystic ovarian syndrome, MET; metformin, and NAC; N-acetylcysteine, and PLA; Placebo.</offsets></p></fn></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label><offsets xml_i="25031" xml_f="25036" txt_i="15626" txt_f="15631">Fig.2</offsets></label><caption><p><offsets xml_i="25056" xml_f="25215" txt_i="15631" txt_f="15790">Correlation between parameters of follicular fluid (FF) in all the population. A. Soluble c-Kit with volume of FF, B. Estradiol (E2), and C. Androstenedione.
R</offsets><sub><offsets xml_i="25220" xml_f="25221" txt_i="15790" txt_f="15791">2</offsets></sub><offsets xml_i="25227" xml_f="25258" txt_i="15791" txt_f="15822">; Determination of coefficient.</offsets></p></caption><graphic xlink:href="Int-J-Fertil-Steril-11-270-g02"></graphic></fig><fig id="F3" orientation="portrait" position="float"><label><offsets xml_i="25401" xml_f="25406" txt_i="15823" txt_f="15828">Fig.3</offsets></label><caption><p><offsets xml_i="25426" xml_f="25625" txt_i="15828" txt_f="16027">Distribution of oocytes retrieved, quality of oocytes and embryos in polycystic ovary syndrome patients undergoing treatment of N-acetylcysteine
(NAC), metformin (MET), NAC+MET and Placebo (control).</offsets></p><p><offsets xml_i="25632" xml_f="25823" txt_i="16028" txt_f="16216">Data are the mean ± SEM. Statistical analyses were performed by ANOVA followed by Tukey’s test for multiple comparisons. Means without a common
letter are significantly different (P&lt;0.05).</offsets></p></caption><graphic xlink:href="Int-J-Fertil-Steril-11-270-g03"></graphic></fig></sec><sec><title><offsets xml_i="25924" xml_f="25980" txt_i="16218" txt_f="16274">Expression profile of GDF-9, BMP-15 and c-Kit in
oocytes</offsets></title><p><offsets xml_i="25991" xml_f="26132" txt_i="16275" txt_f="16413">The level of BMP-15 protein in the mature unfertilized
oocytes and GV oocytes did not differ significantly among
the groups (P&gt;0.05, Figes</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="26162" xml_f="26164" txt_i="16413" txt_f="16415">.4</offsets></xref><offsets xml_i="26171" xml_f="26173" txt_i="16415" txt_f="16417">, </offsets><xref ref-type="fig" rid="F5"><offsets xml_i="26203" xml_f="26211" txt_i="16417" txt_f="16425">5A, D, E</offsets></xref><offsets xml_i="26218" xml_f="27179" txt_i="16425" txt_f="17371">). The expression level
of GDF-9 in the GV oocytes significantly increased in
all groups compared to the placebo (P&lt;0.001) (Fig.4B, D,
F), while for unfertilized mature oocytes, GDF-9 mRNA
and protein levels only significantly increased in the NAC
group (P&lt;0.001, Fig.5B, D, F). The expression of c-kit in
the GV oocytes significantly decreased in the NAC and
MET groups compared to the placebo group (P&lt;0.001),
but not in NAC+MET group (Fig.4C, D, G). The c-kit
expression in the unfertilized mature oocytes significantly
decreased in the NAC group compared to the MET and
other treatment groups (P&lt;0.001), but no significant difference
was found in the MET and NAC+MET groups
when compared to the placebo group (P&gt;0.05, Fig.5C, D,
G). It is important to note that the results for MI oocytes
were similar to GV oocyte; therefore, in this article only
the results of GV were presented. This observation is in
accordance with pervious literature (</offsets><xref rid="B24" ref-type="bibr"><offsets xml_i="27211" xml_f="27213" txt_i="17371" txt_f="17373">24</offsets></xref><offsets xml_i="27220" xml_f="27222" txt_i="17373" txt_f="17375">).</offsets></p><fig id="F4" orientation="portrait" position="float"><label><offsets xml_i="27286" xml_f="27291" txt_i="17376" txt_f="17381">Fig.4</offsets></label><caption><p><offsets xml_i="27311" xml_f="27337" txt_i="17381" txt_f="17407">Effects of NAC and MET on </offsets><italic><offsets xml_i="27345" xml_f="27358" txt_i="17407" txt_f="17420">BMP-15, GDF-9</offsets></italic><offsets xml_i="27367" xml_f="27372" txt_i="17420" txt_f="17425"> and </offsets><italic><offsets xml_i="27380" xml_f="27385" txt_i="17425" txt_f="17430">c-kit</offsets></italic><offsets xml_i="27394" xml_f="27570" txt_i="17430" txt_f="17606"> mRNA and protein expression in immature oocytes (IMO, GV oocytes) of PCOS patients. Results
of reverse transcriptase real-time polymerase chain reaction (PCR) for mRNAs of A. </offsets><italic><offsets xml_i="27578" xml_f="27584" txt_i="17606" txt_f="17612">BMP-15</offsets></italic><offsets xml_i="27593" xml_f="27598" txt_i="17612" txt_f="17617">, B. </offsets><italic><offsets xml_i="27606" xml_f="27611" txt_i="17617" txt_f="17622">GDF-9</offsets></italic><offsets xml_i="27620" xml_f="27625" txt_i="17622" txt_f="17627">, C. </offsets><italic><offsets xml_i="27633" xml_f="27638" txt_i="17627" txt_f="17632">c-kit</offsets></italic><offsets xml_i="27647" xml_f="27900" txt_i="17632" txt_f="17882">, in GV oocytes, D. Immunoblots of BMP-15,
GDF-9 and c-kit from oocyte cell lysates. Densities of E. BMP-15, F. GDF-9 and G. c-kit protein bands in the experimental groups are shown. Means without
a common letter are significantly different (P&lt;0.05).</offsets></p><p><offsets xml_i="27907" xml_f="28006" txt_i="17883" txt_f="17982">NAC; N-acetylcysteine, MET; Metformin, GV; Germinal vesicle, and PCOS; Polycystic ovarian syndrome.</offsets></p></caption><graphic xlink:href="Int-J-Fertil-Steril-11-270-g04"></graphic></fig><fig id="F5" orientation="portrait" position="float"><label><offsets xml_i="28149" xml_f="28154" txt_i="17983" txt_f="17988">Fig.5</offsets></label><caption><p><offsets xml_i="28174" xml_f="28200" txt_i="17988" txt_f="18014">Effects of NAC and MET on </offsets><italic><offsets xml_i="28208" xml_f="28221" txt_i="18014" txt_f="18027">BMP-15, GDF-9</offsets></italic><offsets xml_i="28230" xml_f="28235" txt_i="18027" txt_f="18032"> and </offsets><italic><offsets xml_i="28243" xml_f="28248" txt_i="18032" txt_f="18037">c-kit</offsets></italic><offsets xml_i="28257" xml_f="28445" txt_i="18037" txt_f="18225"> mRNA and protein expression in unfertilized mature oocytes (UMO, MII oocytes) of PCOS
patients. Results of reverse transcriptase real-time polymerase chain reaction (PCR) for mRNAs of A. </offsets><italic><offsets xml_i="28453" xml_f="28459" txt_i="18225" txt_f="18231">BMP-15</offsets></italic><offsets xml_i="28468" xml_f="28473" txt_i="18231" txt_f="18236">, B. </offsets><italic><offsets xml_i="28481" xml_f="28486" txt_i="18236" txt_f="18241">GDF-9</offsets></italic><offsets xml_i="28495" xml_f="28500" txt_i="18241" txt_f="18246">, C. </offsets><italic><offsets xml_i="28508" xml_f="28513" txt_i="18246" txt_f="18251">c-kit</offsets></italic><offsets xml_i="28522" xml_f="28776" txt_i="18251" txt_f="18502"> in MII oocytes, D. Immunoblots
of BMP-15, GDF-9 and c-kit from oocyte cell lysates. Densities of E. BMP-15, F. GDF-9, and G. c-kit protein bands in the experimental groups are
shown. Means without a common letter are significantly different (P&lt;0.05).</offsets></p><p><offsets xml_i="28783" xml_f="28860" txt_i="18503" txt_f="18580">NAC; N-acetylcysteine, MET; Metformin, and PCOS; Polycystic ovarian syndrome.</offsets></p></caption><graphic xlink:href="Int-J-Fertil-Steril-11-270-g05"></graphic></fig></sec></sec><sec sec-type="discussion"><title><offsets xml_i="28989" xml_f="28999" txt_i="18583" txt_f="18593">Discussion</offsets></title><p><offsets xml_i="29010" xml_f="29233" txt_i="18594" txt_f="18817">A typical characteristic of PCOS patient commonly observed
during induction stimulation for ART cycles is increased
number of low quality oocytes which is mainly
related to state of endocrine disorder in these individuals
(</offsets><xref rid="B25" ref-type="bibr"><offsets xml_i="29265" xml_f="29267" txt_i="18817" txt_f="18819">25</offsets></xref><offsets xml_i="29274" xml_f="29527" txt_i="18819" txt_f="19072">). Considering the indispensable role of OSFs in oocyte
development and maturation, many researches have shown
impaired expression of OSFs particularly GDF-9, BMP-
15 and c-kit, may account for low quality oocyte in PCOS
undergoing ovarian stimulation (</offsets><xref rid="B26" ref-type="bibr"><offsets xml_i="29559" xml_f="29561" txt_i="19072" txt_f="19074">26</offsets></xref><offsets xml_i="29568" xml_f="29664" txt_i="19074" txt_f="19170">). This may explain, at
least a part of the folliculogenesis disorders found in these
patients (</offsets><xref rid="B27" ref-type="bibr"><offsets xml_i="29696" xml_f="29698" txt_i="19170" txt_f="19172">27</offsets></xref><offsets xml_i="29705" xml_f="29706" txt_i="19172" txt_f="19173">-</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="29738" xml_f="29740" txt_i="19173" txt_f="19175">29</offsets></xref><offsets xml_i="29747" xml_f="29920" txt_i="19175" txt_f="19348">). Background literature in this filed is very
discrepant. Some authors have reported reduce expression
of GDF-9 with no significant alteration in the expression
of BMP-15 (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="29951" xml_f="29952" txt_i="19348" txt_f="19349">8</offsets></xref><offsets xml_i="29959" xml_f="30066" txt_i="19349" txt_f="19456">), while others have shown no alteration in
expression of these two factors both at RNA and protein
level (</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="30097" xml_f="30098" txt_i="19456" txt_f="19457">9</offsets></xref><offsets xml_i="30105" xml_f="30198" txt_i="19457" txt_f="19550">) in oocyte of PCOS individuals. The exact reason
of such discrepancy is not well understood.</offsets></p><p><offsets xml_i="30205" xml_f="30454" txt_i="19551" txt_f="19800">In continue to our previous study, we demonstrated that
unlike MTE and NAC+MET groups, the administration
of NAC compared to placebo group, improves the maturation
and quality of oocytes and also embryo development
in PCOS patients undergoing ICSI (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="30486" xml_f="30488" txt_i="19800" txt_f="19802">18</offsets></xref><offsets xml_i="30495" xml_f="30676" txt_i="19802" txt_f="19983">). Therefore, in this
we aimed to evaluate whether NAC could alter BMP-15,
GDF-9 and c-kit levels, as the main OSFs in the oocytes
of PCOS patients in comparison to MET and MET+NAC.</offsets></p><p><offsets xml_i="30683" xml_f="30872" txt_i="19984" txt_f="20173">Compelling evidence suggest that GDF-9 and BMP-15
members of the TGFβ superfamily are exclusively expressed
in the oocyte and their expression increases as follicle development
progresses (</offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="30904" xml_f="30906" txt_i="20173" txt_f="20175">30</offsets></xref><offsets xml_i="30913" xml_f="31007" txt_i="20175" txt_f="20269">). During postnatal ovarian development,
c-kit mRNA and protein are localized in the oocytes
(</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="31038" xml_f="31039" txt_i="20269" txt_f="20270">6</offsets></xref><offsets xml_i="31046" xml_f="31084" txt_i="20270" txt_f="20308">), and in this regard Brankin et al. (</offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="31116" xml_f="31118" txt_i="20308" txt_f="20310">31</offsets></xref><offsets xml_i="31125" xml_f="31369" txt_i="20310" txt_f="20554">) has shown a relation
between KL/c-kit interaction with antrum formation,
steroidogenesis and oocyte quality. Furthermore, genetic and
descriptive studies have implicated the involvement of c-kit
receptor and its ligand, KL, in oocyte growth (</offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="31401" xml_f="31403" txt_i="20554" txt_f="20556">32</offsets></xref><offsets xml_i="31410" xml_f="31412" txt_i="20556" txt_f="20558">).</offsets></p><p><offsets xml_i="31419" xml_f="31597" txt_i="20559" txt_f="20737">Low GDF-9 levels is associated with abnormally increased
KL level in PCOS, which could lead to abnormal
ovarian features such as enlarged oocytes and increased
follicle numbers (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="31628" xml_f="31629" txt_i="20737" txt_f="20738">7</offsets></xref><offsets xml_i="31636" xml_f="31638" txt_i="20738" txt_f="20740">, </offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="31670" xml_f="31672" txt_i="20740" txt_f="20742">32</offsets></xref><offsets xml_i="31679" xml_f="31797" txt_i="20742" txt_f="20860">). In PCOS patients, the GDF-9
mRNA level within the oocytes is lower than in oocyte
derived from normal individuals (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="31828" xml_f="31829" txt_i="20860" txt_f="20861">8</offsets></xref><offsets xml_i="31836" xml_f="31951" txt_i="20861" txt_f="20976">), and it is believed
that there is a negative association between GDF-9 expression
and KL/c-kit expression. Tuck (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="31982" xml_f="31983" txt_i="20976" txt_f="20977">7</offsets></xref><offsets xml_i="31990" xml_f="32240" txt_i="20977" txt_f="21227">) believes that
excess androgens may act to further reduce the inhibitory
effect of GDF-9, thus resulting in an abnormal increase in
the KL/c-kit protein level in PCOS individual. Considering
the inverse relationship between c-kit and GDF-9 in
PCOS (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="32271" xml_f="32272" txt_i="21227" txt_f="21228">7</offsets></xref><offsets xml_i="32279" xml_f="32281" txt_i="21228" txt_f="21230">, </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="32312" xml_f="32313" txt_i="21230" txt_f="21231">8</offsets></xref><offsets xml_i="32320" xml_f="32322" txt_i="21231" txt_f="21233">, </offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="32354" xml_f="32356" txt_i="21233" txt_f="21235">32</offsets></xref><offsets xml_i="32363" xml_f="32460" txt_i="21235" txt_f="21332">), therefore, improving the expression of
GDF-9 is expected to cause a reduction in c-kit levels.</offsets></p><p><offsets xml_i="32467" xml_f="32894" txt_i="21333" txt_f="21760">Our results displayed a significant increase in the expression
of GDF-9 in the unfertilized mature oocytes of
PCOS patients after administration of NAC compared
to MET, indicating that NAC, as an anti-oxidant/antiapoptotic
agent, could enhance the expression of GDF-9
through inhibiting the activity of NF-kB and AP-1 transcription
factors, therefore affecting the activity of MAPkinase
signaling and related genes expression (</offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="32926" xml_f="32928" txt_i="21760" txt_f="21762">33</offsets></xref><offsets xml_i="32935" xml_f="33054" txt_i="21762" txt_f="21881">), which
may be able to alleviate PCOS follicular disorders and
prevent follicular developmental detention and atresia.</offsets></p><p><offsets xml_i="33061" xml_f="33478" txt_i="21882" txt_f="22299">Our study, in agreement with aforementioned studies, also
showed a significant decrease in the expression of c-kit in
the oocytes of PCOS patients and also the soluble c-kit protein
in the FF following administration of NAC compared to
control. In addition, evidence has indicated the relationship
between KL/c-kit system with MAPK pathway and/or PI3K/
Akt pathway, which are both necessary for follicle development
(</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="33510" xml_f="33512" txt_i="22299" txt_f="22301">34</offsets></xref><offsets xml_i="33519" xml_f="33796" txt_i="22301" txt_f="22578">). It is likely that NAC decreases the expression
of c-kit through interference in MAPK pathway, all of this
could be the underlying reason in the role of NAC in preventing
follicular developmental detention and atresia and
alleviation of follicular disorders in PCOS patients.</offsets></p><p><offsets xml_i="33803" xml_f="34068" txt_i="22579" txt_f="22844">Although the FF content may be an invaluable hallmark
for PCOS diagnosis, but the NAC ability to modulate
these intra-ovarian factors of the oocyte may have interesting
pharmacological perspectives for clinical management
of PCOS patients. According to literature (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="34099" xml_f="34100" txt_i="22844" txt_f="22845">7</offsets></xref><offsets xml_i="34107" xml_f="34109" txt_i="22845" txt_f="22847">, </offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="34140" xml_f="34141" txt_i="22847" txt_f="22848">8</offsets></xref><offsets xml_i="34148" xml_f="34150" txt_i="22848" txt_f="22850">, </offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="34182" xml_f="34184" txt_i="22850" txt_f="22852">32</offsets></xref><offsets xml_i="34191" xml_f="34470" txt_i="22852" txt_f="23131">),
there is an inverse relationship between c-kit and GDF-9.
Therefore, improves expression of GDF-9 by NAC treatment,
is expected to follow by a reduction in c-Kit and
indeed MET appears to mask this effect of NAC, how this
masking effect is performed, remains to be elucidated.</offsets></p><p><offsets xml_i="34477" xml_f="34628" txt_i="23132" txt_f="23283">In this regard it has been shown that with increased follicular
size and E2 production, the amount of soluble c-kit
protein in human FF also increase (</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="34660" xml_f="34662" txt_i="23283" txt_f="23285">35</offsets></xref><offsets xml_i="34669" xml_f="34817" txt_i="23285" txt_f="23433">), which is consistent
with the correlation observed in this study between
soluble c-kit with the FF volume, E2, and androstenedione
concentrations.</offsets></p><p><offsets xml_i="34824" xml_f="35062" txt_i="23434" txt_f="23672">It has been demonstrated that the excess secretion of
anti-mullerian hormone (AMH) in the FF of PCOS patients
may directly inhibit the production of OSFs such
as GDF-9 and BMP-15, which can explain the low levels
of OSFs in PCOS oocytes (</offsets><xref rid="B36" ref-type="bibr"><offsets xml_i="35094" xml_f="35096" txt_i="23672" txt_f="23674">36</offsets></xref><offsets xml_i="35103" xml_f="35187" txt_i="23674" txt_f="23758">). Our findings showed
a reduction in the AMH level in the FF of NAC treated
group (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="35219" xml_f="35221" txt_i="23758" txt_f="23760">18</offsets></xref><offsets xml_i="35228" xml_f="35442" txt_i="23760" txt_f="23974">). Although this reduction was not statistically
significant but may be considered as an underlying reason
for the increased levels of GDF-9 in the NAC treated patients.
Moreover, in agreement with other findings (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="35473" xml_f="35474" txt_i="23974" txt_f="23975">8</offsets></xref><offsets xml_i="35481" xml_f="35483" txt_i="23975" txt_f="23977">, </offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="35514" xml_f="35515" txt_i="23977" txt_f="23978">9</offsets></xref><offsets xml_i="35522" xml_f="35623" txt_i="23978" txt_f="24079">),
our study revealed no significant difference in the level of
BMP-15 mRNA among the studies groups.</offsets></p></sec><sec sec-type="conclusions"><title><offsets xml_i="35668" xml_f="35678" txt_i="24081" txt_f="24091">Conclusion</offsets></title><p><offsets xml_i="35689" xml_f="36256" txt_i="24092" txt_f="24659">Considering the fact that NAC improves oocyte maturation
and embryo quality, and decreases the rate of immature
oocytes in women with PCOS while being a safe and welltolerated
agent, we suggest the administration of NAC as
an alternative to other insulin-sensitizing agents like MET.
Therefore, the present study argues that NAC possibly improves
the oocyte quality of PCOS patients compared to
MET through modulating the c-kit and GDF-9 expression,
indicating that NAC supplement may be a therapeutic alternative
to the insulin-sensitizing agents in PCOS management.</offsets></p></sec></body><back><ack><p>We thank the members of the IVF unit of the Infertility
Research Center of the Academic Center for Education,
Culture and Research (ACECR), Qom. This research was
financially supported by Arak University. The authors declare
that there is no conflict of interest.</p></ack><bio id="d35e740"><title>Author's contributions</title><p>E.C., M.S.M., S.M.A.S.; Participated in study design,
data collection and evaluation, drafting and statistical analysis.
M.H.N.E., E.C.; Performed follicle collection and prepared
oocytes for ICSI pertaining to this component of the
study. E.C., M.S.M., M.H.N.E.; Contributed extensively in
interpretation of the data and the conclusion. B.A., E.C.;
Conducted molecular experiments and RT-qPCR analysis.
All authors performed editing and approving the final version
of this paper for submission, also participated in the
finalization of the manuscript and approved the final draft.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teede</surname><given-names>H</given-names></name><name><surname>Deeks</surname><given-names>A</given-names></name><name><surname>Moran</surname><given-names>L</given-names></name></person-group><article-title>Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan</article-title><source>BMC Med</source><year>2010</year><volume>8</volume><fpage>41</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">20591140</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balen</surname><given-names>AH</given-names></name><name><surname>Rutherford</surname><given-names>AJ</given-names></name></person-group><article-title>Managing anovulatory infertility and polycystic ovary syndrome</article-title><source>BMJ</source><year>2007</year><volume>335</volume><issue>7621</issue><fpage>663</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">17901517</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>HL</given-names></name></person-group><article-title>Extra-and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence</article-title><source>Hum Reprod Update</source><year>2011</year><volume>17</volume><issue>1</issue><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">20639519</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilchrist</surname><given-names>RB</given-names></name><name><surname>Lane</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>JG</given-names></name></person-group><article-title>Oocyte-secreted factors: regulators of cumulus cell function and oocyte quality</article-title><source>Hum Reprod Update</source><year>2008</year><volume>14</volume><issue>2</issue><fpage>159</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">18175787</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knight</surname><given-names>PG</given-names></name><name><surname>Glister</surname><given-names>C</given-names></name></person-group><article-title>TGF-β superfamily members and ovarian follicle development</article-title><source>Reproduction</source><year>2006</year><volume>132</volume><issue>2</issue><fpage>191</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">16885529</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celestino</surname><given-names>JJH</given-names></name><name><surname>Matos</surname><given-names>MHT</given-names></name><name><surname>Saraiva</surname><given-names>MVA</given-names></name><name><surname>Figueiredo</surname><given-names>JR</given-names></name></person-group><article-title>Regulation of ovarian folliculogenesis by Kit Ligand and the c-Kit system in mammals</article-title><source>Anim Reprod</source><year>2009</year><volume>6</volume><issue>3</issue><fpage>431</fpage><lpage>439</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuck</surname><given-names>AR</given-names></name><name><surname>Robker</surname><given-names>RL</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><name><surname>Hickey</surname><given-names>TE</given-names></name></person-group><article-title>Expression and localisation of c-kit and KITL in the adult human ovary</article-title><source>J Ovarian Res</source><year>2015</year><volume>8</volume><fpage>31</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">26008799</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira Filho</surname><given-names>FL</given-names></name><name><surname>Baracat</surname><given-names>EC</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Suh</surname><given-names>CS</given-names></name><name><surname>Matsui</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>RJ</given-names></name><etal></etal></person-group><article-title>Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><issue>3</issue><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="pmid">11889206</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>SY</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name></person-group><article-title>Expression of growth differentiation factor-9 and bone morphogenetic protein-15 in oocytes and cumulus granulosa cells of patients with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><issue>1</issue><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">19376510</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persani</surname><given-names>L</given-names></name><name><surname>Rossetti</surname><given-names>R</given-names></name><name><surname>Di Pasquale</surname><given-names>E</given-names></name><name><surname>Cacciatore</surname><given-names>C</given-names></name><name><surname>Fabre</surname><given-names>S</given-names></name></person-group><article-title>The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders</article-title><source>Hum Reprod Update</source><year>2014</year><volume>20</volume><issue>6</issue><fpage>869</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">24980253</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>S</given-names></name><name><surname>Falbo</surname><given-names>A</given-names></name><name><surname>La Sala</surname><given-names>GB</given-names></name></person-group><article-title>Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials</article-title><source>Reprod Biol Endocrinol</source><year>2014</year><volume>12</volume><fpage>3</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">24387273</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>JM</given-names></name><name><surname>Flight</surname><given-names>IH</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name></person-group><article-title>Metformin in polycystic ovary syndrome: systematic review and meta-analysis</article-title><source>BMJ</source><year>2003</year><volume>327</volume><issue>7421</issue><fpage>951</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">14576245</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kjøtrød</surname><given-names>SB</given-names></name><name><surname>von Düring</surname><given-names>V</given-names></name><name><surname>Carlsen</surname><given-names>SM</given-names></name></person-group><article-title>Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study</article-title><source>Hum Reprod</source><year>2004</year><volume>19</volume><issue>6</issue><fpage>1315</fpage><lpage>1322</lpage><pub-id pub-id-type="pmid">15117902</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Orsi</surname><given-names>N</given-names></name><name><surname>Barth</surname><given-names>JH</given-names></name><name><surname>Balen</surname><given-names>AH</given-names></name></person-group><article-title>The use of metformin for women with PCOS undergoing IVF treatment</article-title><source>Hum Reprod</source><year>2006</year><volume>21</volume><issue>6</issue><fpage>1416</fpage><lpage>1425</lpage><pub-id pub-id-type="pmid">16501038</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Delay in oocyte aging in mice by the antioxidant N-acetyl-l-cysteine (NAC)</article-title><source>Hum Reprod</source><year>2012</year><volume>27</volume><issue>5</issue><fpage>1411</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">22357770</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>R</given-names></name><name><surname>Montanaro</surname><given-names>L</given-names></name><name><surname>Pasquinelli</surname><given-names>G</given-names></name><name><surname>Magnani</surname><given-names>V</given-names></name><name><surname>Tamburini</surname><given-names>F</given-names></name><name><surname>Takeuchi</surname><given-names>T</given-names></name><etal></etal></person-group><source>Effects of N-Acetyl-Cystein on GDF-9 expression and BCL-2/BAX ratio in long-term culture of frozen/thawed human ovarian tissue.25th Annual Meeting of ESHRE; 2009 Jun-Jul 28-1; Amsterda; the Netherlands</source><publisher-name>25th Annual Meeting of ESHRE; 2009 Jun-Jul 28-1; Amsterda; the Netherlands</publisher-name><year>2009</year></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoodi</surname><given-names>M</given-names></name><name><surname>Soleimani Mehranjani</surname><given-names>M</given-names></name><name><surname>Shariatzadeh</surname><given-names>SM</given-names></name><name><surname>Eimani</surname><given-names>H</given-names></name><name><surname>Shahverdi</surname><given-names>A</given-names></name></person-group><article-title>N-acetylcysteine improves function and follicular survival in mice ovarian grafts through inhibition of oxidative stress</article-title><source>Reprod Biomed Online</source><year>2015</year><volume>30</volume><issue>1</issue><fpage>101</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">25458850</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacchinelli</surname><given-names>A</given-names></name><name><surname>Venturella</surname><given-names>R</given-names></name><name><surname>Lico</surname><given-names>D</given-names></name><name><surname>Di Cello</surname><given-names>A</given-names></name><name><surname>Lucia</surname><given-names>A</given-names></name><name><surname>Rania</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>The efficacy of inositol and N-Acetyl cysteine administration (Ovaric HP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance</article-title><source>Obstet Gynecol Int J</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheraghi</surname><given-names>E</given-names></name><name><surname>Mehranjani</surname><given-names>MS</given-names></name><name><surname>Shariatzadeh</surname><given-names>MA</given-names></name><name><surname>Esfahani</surname><given-names>MH</given-names></name><name><surname>Ebrahimi</surname><given-names>Z</given-names></name></person-group><article-title>N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin</article-title><source>Reprod Fertil Dev</source><year>2016</year><volume>28</volume><issue>6</issue><fpage>723</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">25482371</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><collab>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab><article-title>Revised 2003.consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2004</year><volume>81</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulghesu</surname><given-names>AM</given-names></name><name><surname>Ciampelli</surname><given-names>M</given-names></name><name><surname>Muzj</surname><given-names>G</given-names></name><name><surname>Belosi</surname><given-names>C</given-names></name><name><surname>Selvaggi</surname><given-names>L</given-names></name><name><surname>Ayala</surname><given-names>GF</given-names></name><etal></etal></person-group><article-title>N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2002</year><volume>77</volume><issue>6</issue><fpage>1128</fpage><lpage>1135</lpage><pub-id pub-id-type="pmid">12057717</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elnashar</surname><given-names>A</given-names></name><name><surname>Fahmy</surname><given-names>M</given-names></name><name><surname>Mansour</surname><given-names>A</given-names></name><name><surname>Ibrahim</surname><given-names>K</given-names></name></person-group><article-title>N-acetyl cysteine vs.metformin in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective randomized controlled study</article-title><source>Fertil Steril</source><year>2007</year><volume>88</volume><issue>2</issue><fpage>406</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">17335818</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oner</surname><given-names>G</given-names></name><name><surname>Muderris</surname><given-names>II</given-names></name></person-group><article-title>Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2011</year><volume>159</volume><issue>1</issue><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">21831508</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>LN</given-names></name><name><surname>Liang</surname><given-names>XY</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>MF</given-names></name></person-group><article-title>Abnormal expression of growth differentiation factor 9 and bone morphogenetic protein 15 in stimulated oocytes during maturation from women with polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2011</year><volume>96</volume><issue>2</issue><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">21669410</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumesic</surname><given-names>DA</given-names></name><name><surname>Abbott</surname><given-names>DH</given-names></name></person-group><article-title>Implications of Polycystic ovary syndrome (pcos) on oocyte development</article-title><source>Semin Reprod Med</source><year>2008</year><volume>26</volume><issue>1</issue><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">18181083</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surcel</surname><given-names>M</given-names></name><name><surname>Stamatian</surname><given-names>F</given-names></name></person-group><article-title>Folliculogenesis disturbances within the polycystic ovarian syndrome and possible consequences on oocyte quality</article-title><source>Acta Endocrinologica (Buc)</source><year>2012</year><volume>8</volume><issue>2</issue><fpage>267</fpage><lpage>287</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimasaki</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>RK</given-names></name><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>Erickson</surname><given-names>GF</given-names></name></person-group><article-title>The bone morphogenetic protein system in mammalian reproduction</article-title><source>Endocr Rev</source><year>2004</year><volume>25</volume><issue>1</issue><fpage>72</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">14769828</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>XE</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>XM</given-names></name><etal></etal></person-group><article-title>High bone morphogenetic protein-15 level in follicular fluid is associated with high quality oocyte and subsequent embryonic development</article-title><source>Hum Reprod</source><year>2007</year><volume>22</volume><issue>6</issue><fpage>1526</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">17347167</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>LL</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>XY</given-names></name></person-group><article-title>Inhibitory effects of controlled ovarian stimulation on the expression of GDF9 and BMP15 in oocytes from women with PCOS</article-title><source>J Assist Reprod Genet</source><year>2013</year><volume>30</volume><issue>10</issue><fpage>1313</fpage><lpage>1318</lpage><pub-id pub-id-type="pmid">23912750</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>F</given-names></name><name><surname>McTavish</surname><given-names>KJ</given-names></name><name><surname>Shimasaki</surname><given-names>S</given-names></name></person-group><article-title>Integral role of GDF-9 and BMP-15 in ovarian function</article-title><source>Mol Reprod Dev</source><year>2011</year><volume>78</volume><issue>1</issue><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">21226076</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brankin</surname><given-names>V</given-names></name><name><surname>Hunter</surname><given-names>MG</given-names></name><name><surname>Horan</surname><given-names>TL</given-names></name><name><surname>Armstrong</surname><given-names>DG</given-names></name><name><surname>Webb</surname><given-names>R</given-names></name></person-group><article-title>The expression patterns of Mrna-encoding stem cell factor, internal stem cell factor and c-kit in the prepubertal and adult porcine ovary</article-title><source>J Anat</source><year>2004</year><volume>205</volume><issue>5</issue><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">15575888</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutt</surname><given-names>K</given-names></name><name><surname>McLaughlin</surname><given-names>EA</given-names></name><name><surname>Holland</surname><given-names>MK</given-names></name></person-group><article-title>Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis</article-title><source>Mol Hum Reprod</source><year>2006</year><volume>12</volume><issue>2</issue><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">16481408</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Flora</surname><given-names>S</given-names></name><name><surname>Izzotti</surname><given-names>A</given-names></name><name><surname>D'Agostini</surname><given-names>F</given-names></name><name><surname>Balansky</surname><given-names>RM</given-names></name></person-group><article-title>Mechanisms of Nacetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points</article-title><source>Carcinogenesis</source><year>2001</year><volume>22</volume><issue>7</issue><fpage>999</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">11408342</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name></person-group><article-title>Stem cell factor (SCF)-kit mediated phosphatidylinositol 3 (PI3) kinase signaling during mammalian oocyte growth and early follicular development</article-title><source>Front Biosci</source><year>2006</year><volume>11</volume><fpage>126</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">16146719</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanikawa</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Mitsunari</surname><given-names>M</given-names></name><name><surname>Onohara</surname><given-names>Y</given-names></name><name><surname>Iwabe</surname><given-names>T</given-names></name><name><surname>Terakawa</surname><given-names>N</given-names></name></person-group><article-title>Expression of c-kit messenger ribonucleic acid in human oocyte and presence of soluble c-kit in follicular fluid</article-title><source>J Clin Endocrinol Metab</source><year>1998</year><volume>83</volume><issue>4</issue><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">9543148</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desforges-Bullet</surname><given-names>V</given-names></name><name><surname>Gallo</surname><given-names>C</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Pigny</surname><given-names>P</given-names></name><name><surname>Dewailly</surname><given-names>D</given-names></name><name><surname>Catteau-Jonard</surname><given-names>S</given-names></name></person-group><article-title>Increased anti-Müllerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization</article-title><source>Fertil Steril</source><year>2010</year><volume>94</volume><issue>1</issue><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">19361798</pub-id></element-citation></ref></ref-list></back></article>